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The envelope proteins of hepatitis C virus (HCV) are the likely targets of neutralizing antibodies and their molecular and
functional characterization is relevant for vaccine development. We previously showed that surface-expressed E2 is a better
immunogen than intracellular E2 and, therefore, we were interested in exploring more efficient ways to present E2 protein
on the cell surface. We found that E2 targeted to the cell surface by replacement of its transmembrane domain did not bring
E1 to the surface although E1 could be expressed independently on the cell surface if its transmembrane domain was
similarly replaced. FACS analysis suggested that E2 expressed on the cell surface acquired its native conformation more
efficiently when truncated at aa 661 than when truncated at aa 715. The shorter form of truncated E2 better retained the
ability to bind the second extracellular loop (EC2) of CD81, the putative HCV receptor. Interestingly, deletion of the
hypervariable region 1 (HVR1) did not perceptibly alter E2 structure; cell-surface forms of E2 lacking the HVR1 remained
reactive with conformation-sensitive MAbs and were able to bind recombinant EC2 of CD81. © 2000 Academic Press
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eINTRODUCTION
The hepatitis C virus (HCV) is a member of the Flavi-
viridae family of viruses. HCV has a single-strand posi-
tive-sense RNA genome that encodes a polyprotein of
approximately 3000 amino acids; the structural proteins
[core, two glycoproteins (E1, E2)] constitute the amino-
terminal third of the polyprotein (Rice, 1996). The HCV
envelope glycoproteins are heavily glycosylated (re-
viewed in Rice, 1996) and each contains a hydrophobic
domain at its carboxy-terminus that acts as a membrane
anchor (Cocquerel et al., 1998; Matsuura et al., 1994;
Michalak et al., 1997; Mizushima et al., 1994). When
xpressed in mammalian cells, only a fraction of newly
ynthesized E1 and E2 fold correctly; the rest are mis-
olded and form disulfide-linked aggregates that do not
each the secretory pathway (Deleersnyder et al., 1997;
ubuisson, 1998; Dubuisson and Rice, 1996). “Well-
olded” E1 and E2 glycoproteins form heterodimers that
re stabilized by noncovalent interactions (Deleersnyder
t al., 1997; Dubuisson et al., 1994; Grakoui et al., 1993;
alston et al., 1993). These heterodimers are most likely
unctional subunits of HCV virions: they have been char-
cterized by electron microscopy and by immunoprecipi-
ation with conformation-sensitive monoclonal antibod-
es (Deleersnyder et al., 1997; Dubuisson et al., 1994;
ubuisson and Rice, 1996). The fact that these het-
1 To whom correspondence and reprint requests should be ad-
ressed at present address: Liver Unit, Hospital Clinic, Villarroel 170,(
i
arcelona 08036, Spain. Fax: 134 93 451 5522. E-mail: XFORNS@
linic.ub.es.
75rodimers are retained in the ER suggests that HCV, like
ther members of the Flaviviridae family, buds from this
ntracellular compartment and not from the cell surface
embrane.
The lack of a reliable cell culture system for HCV has
indered analysis of how HCV infects cells or assembles
nto virions. Only recently, Pileri et al. (1998) proposed
hat CD81, a 25-kDa molecule belonging to the tet-
aspanin family, is the putative HCV receptor. However,
nother study suggests that HCV and other members of
he Flaviviridae family form complexes with very-low-
ensity lipoproteins (VLDL) or low-density lipoproteins
LDL) and enter cells by endocytosis via the LDL receptor
Agnello et al., 1999).
Because of the medical importance of hepatitis C,
here is a great effort to develop an HCV vaccine. As the
nvelope proteins most likely contain neutralization
pitopes (Farci et al., 1996; Shimizu et al., 1996; Weiner et
l., 1992), these proteins have been the major focus of
accine research. Vaccination of chimpanzees with pu-
ified recombinant E1/E2 heterodimers generated a hu-
oral immune response and protected chimpanzees
rom a low-dose challenge with homologous HCV (Choo
t al., 1994), but not with a closely related but heterolo-
ous strain (Houghton et al., 1997). DNA vaccines, in
hich the target protein is expressed in vivo, have also
een used to induce antibodies to HCV E2. Since dele-
ion or replacement of the transmembrane domain (TMD)
f E2 enabled secretion (Matsuura et al., 1994; Michalak
t al., 1997; Selby et al., 1994) or cell surface expressionCocquerel et al., 1998; Forns et al., 1999b), respectively,
t was possible to alter the cellular location of the E2
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
i1995).
soluble
76 FORNS ET AL.protein expressed from DNA vaccine constructs. Such
alterations increased the immunogenicity of E2; plas-
mids encoding secreted or cell surface-expressed E2
generated a stronger humoral immune response in mice,
tamarins, or rhesus macaques than did plasmids encod-
ing an intracellular E2 (Forns et al., 1999b; Fournillier et
al., 1998, 1999; Saito et al., 1997). However, since these
species are not susceptible to HCV infection, it is not
known whether such plasmid vaccine candidates elic-
ited protective immune responses. When two chimpan-
zees were immunized with DNA encoding a cell surface-
expressed E2 (truncated at aa 715) and challenged with
homologous monoclonal HCV, the chimpanzees were
not protected from HCV infection although an ELISA
demonstrated that they had antibodies to the E2 glyco-
protein at the time of challenge (Forns et al., 2000). The
lack of sterilizing immunity might indicate that the sur-
face-expressed E2 was presented to the immune system
in a form that could not effectively elicit neutralizing
antibodies. This result has prompted us to introduce
additional modifications into E2 protein expressed on the
cell surface and to compare such surface-expressed
forms of E2 for their ability to interact with a panel of
conformation-sensitive antibodies and to bind to the sec-
ond extracellular loop (EC2) of the putative HCV receptor,
CD81.
RESULTS
HCV E2 protein truncated at aa 661 reaches the cell
membrane more efficiently than does E2 truncated
at aa 715
Huh-7 cells transfected with pE2, pE2surf-715, or
pE2surf-661 were analyzed for the expression of E2. The
E2surf glycoproteins were truncated at their carboxy-
T
Reactivity of Rabbit Hyperimmune Sera
Serum
Location within
HCV polyprotein
(strain H77) Immunofluorescenceb
LMF86 390–410 111
521 645–662 11
523 445–468 6
527 584–600 2
FOR-1 517–535 111
554 460–483 11
a Reactivity in the different assays was measured on a scale from 2
n a test not confirmed in repeated experiments.
b Measured in Huh-7 cells transfected with pE2.
c Tested on lysates of Huh-7 cells transfected with pE2surf-715.
d Performed with a recombinant soluble HCV E2 (Lesniewsky et al.,
e Serum dilution that inhibited binding of recombinant CD81 EC2 toterminus and had the transmembrane domain (TMD) of
E2 replaced with that of platelet-derived growth factorreceptor (PDGFR), a cellular glycoprotein normally ex-
pressed on the cell surface. We first tested fivefold serial
dilutions of cell lysates obtained from Huh-7 cells trans-
fected with pE2, pE2surf-715, or pE2surf-661 by Western
blot; staining with human plasma H79, which contains
anti-E2, did not show significant differences in the levels
of expression among these constructs (data not shown).
By immunofluorescence microscopy, E2 protein was de-
tected at similar levels with anti-HVR1 rabbit hyperim-
mune serum (LMF86, Table 1) in the cytoplasm of per-
meabilized cells transfected with any of the three plas-
mids. In contrast, when nonpermeabilized cells were
stained, E2 was found on the cell membrane of cells
transfected with pE2surf-715 or pE2surf-661, but not with
pE2. Therefore, consistent with data from a previous
report (Flint et al., 1999b), we found that E2 truncated at
either amino acid 661 or 715 could be expressed on the
cell surface.
To establish whether the efficiency of transport to the
cell surface varied according to the E2 modification, we
transfected Huh-7 cells with pE2surf-661 or with pE2surf-
715 and quantified intracellular and cell surface expres-
sion of the protein at 24, 48, and 72 h by flow cytometric
analysis (FACS) of cells stained with anti-HVR1 rabbit
hyperimmune serum (which reacts equally well with the
two truncated forms of E2). The proportion of cells ex-
pressing E2 on the cell surface was calculated by divid-
ing the number of cells positive for membrane staining
by the number of cells positive for intracellular staining.
The same number of cells was analyzed for each con-
struct, a negative control was included in each experi-
ment, and results were confirmed in duplicate experi-
ments. For pE2surf-661, 28% of Huh-7 cells expressing E2
had E2 protein on the cell surface at 24 h posttransfec-
tion (Fig. 1). This proportion increased to 49% at 48 h and
against Different Domains of HCV E2a
rn
b Immunoprecipitationc ELISAd
CD81 EC2–E2
inhibitione
1 111 111 2
6 111 2
6 1 2
2 11 2
11 111 1/40
1 11 2
tivity) to 111 (maximum reactivity). 6 values indicate weak positivity
E2 (Lesniewsky et al., 1995) by 50%.ABLE 1
Raised
Weste
blot
11
2
6
2
11
11
(no reacdecreased to 24% at 72 h posttransfection. The figures
for pE2surf-715 were 8% at 24 h, 25% at 48 h, and 23% at
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77CELL SURFACE-EXPRESSED HCV E2 GLYCOPROTEINS72 h. Thus, E2surf-661 apparently was displayed on the
cell surface more efficiently than was E2surf-715. The
fact that only a fraction of the cells expressing E2surf-661
or E2surf-715 intracellularly had detectable E2 proteins
on the cell surface is most likely explained by the sen-
sitivity of our detection method since more protein is
accumulated intracellularly than on the cell surface. The
majority of expressed E2 forms disulfide-linked aggre-
gates that are not transported to the cell surface; these
aggregates are stained only when the cells are fixed and
permeabilized.
Cell surface-expressed E2 does not transport
full-length E1 to the cell membrane
As it was previously shown that E1 complexes with E2,
we wanted to establish whether our cell surface-ex-
pressed E2 was able to direct full-length E1 to the cell
surface. For this purpose, cells were transfected with a
plasmid (pE1E2surf-715) encoding complete E1 followed
by E2 modified for expression on the cell surface (aa
192–715). Cells were differentially stained for both E1 and
E2 and examined by immunofluorescence microscopy
(Fig. 2). Although both proteins were detected in the
cytoplasm, only E2 was found on the cell membrane,
indicating that E1 and the surface-expressed E2 acted
independently in this case, as also found in a previous
report (Flint et al., 1999b). However, we demonstrated
hat E1 could be detected with MAb A4 on the surface of
ells transfected with pE1surf-347, in which the hydro-
hobic domain of E1 was replaced with that of PDGFR
data not shown).
2surf-661 and E2surf-715 differ in conformation and
n binding to recombinant EC2 of CD81
FIG. 1. E2-surf 661 is targeted to the cell membrane more efficiently
han is E2surf-715. FACS analysis showing the percentage of E2-
ositive cells that have E2 on the cell surface at 24, 48, and 72 h after
ransfection. Surf, surface stained (nonpermeabilized). Cyto, cytoplasm
tained (permeabilized cells). Open bars, cells transfected with
E2surf-715. Filled bars, cells transfected with pE2surf-661.We studied the reactivity of E2, E2surf-661, E2surf-715,
nd a soluble form of E2 (Lesniewsky et al., 1995) with aanel of rabbit hyperimmune sera, generated against
nown E2 epitopes (Tables 1 and 2). We also compared
he reactivity of these rabbit sera with human and mouse
onoclonal E2 antibodies (da Silva Cardoso et al., 1998;
eleersnyder et al., 1997; Habersetzer et al., 1998) when
tested against E2, E2surf-661, and E2surf-715 (Tables 2
and 3). Except for one (MAb H2) of the four conformation-
sensitive MAbs tested, we did not observe any signifi-
cant differences by immunofluorescence microscopy in
the reactivity of the antibodies with the two surface-
expressed forms of E2. MAb H2 is believed to recognize
“native” E2, as it occurs in E1/E2 heterodimers. Cells
expressing E2surf-661 on the cell surface were stained
intensely with MAb H2, whereas the fluorescence inten-
sity was much weaker in cells expressing E2surf-715 on
the cell surface (Fig. 3A). The quantitative difference in
surface reactivity of the two truncated E2 proteins was
confirmed by flow cytometric analyses (Fig. 3B). After
staining with MAb H2, five times as many cells scored
positive in cells transfected with pE2surf-661 (1.37%) than
in cells transfected with pE2surf-715 (0.24%) and the
mean fluorescence intensity differed by twofold (264 and
138, respectively). After staining with anti-HVR1 (or MAb
H53, data not shown) we observed a significantly smaller
difference in the proportion of positive cells (3.3% versus
2.2%) and fluorescence intensity (513 versus 458). These
findings suggest that the conformation of E2surf-661 and
E2surf-715 differs with respect to a conformational
epitope recognized by MAb H2, but not with respect to
additional conformational epitopes recognized by three
other conformation-sensitive antibodies.
The binding of a soluble recombinant EC2 of human
CD81 (Pileri et al., 1998) to E2surf-661 or E2surf-715
expressed on the surface of live cells was studied by
immunofluorescence microscopy and flow cytometry.
Recombinant EC2 was detected by a mouse monoclonal
antibody that recognizes thioredoxin expressed in fusion
with EC2. E2 was monitored with anti-HVR1 rabbit hy-
perimmune serum (LFM86) or with MAb H53, since they
recognized both chimeric forms of E2 equally well. Dou-
ble-staining with rabbit anti-HVR1 and mouse anti-thiore-
doxin confirmed that cells binding EC2 had E2 on the cell
surface (Fig. 3C). Immunofluorescence microscopy of
nonpermeabilized cells demonstrated that EC2 bound to
significantly more cells expressing E2surf-661 than ex-
pressing E2surf-715 (Fig. 3A, Table 3). This finding was
confirmed by flow cytometry analysis (Fig. 3C). The per-
centage of transfected cells expressing E2 was 5.4%
for E2surf-661 and 4.1% for E2surf-715 (background sub-
tracted). The proportion of cells expressing E2 that
bound EC2 was significantly higher for E2surf-661 (44%)
than for E2surf-715 (3%). These results suggested that
the additional amino acids in E2surf-715 decreased its
ability to bind EC2 of CD81.
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78 FORNS ET AL.Inhibition of CD81 EC2 binding to recombinant E2
The six rabbit hyperimmune sera generated in the
present study, which reacted similarly with E2surf-661
and E2surf-715, were tested by ELISA to determine
whether they could inhibit the binding of recombinant
CD81 EC2 to a soluble form of E2 (Lesniewski et al.,
1995) (Table 1). Flint et al. (1999a) had reported that the
binding site in E2 that interacts with CD81 is conforma-
tional and involves aa 480–493 and 554–569. None of our
rabbit hyperimmune sera were to peptides within these
regions. However, the rabbit serum raised against pep-
tide 517–535, between the first and the second binding
domains determined by Flint et al. (1999a), inhibited the
binding of soluble E2 to CD81 EC2 (Table 1). Antibodies
against the 517–535 epitope are also present in plasma
H79 (from a chronically infected patient), which neutral-
ized homologous HCV (Farci et al., 1994). Plasma H79
inhibited EC2 binding by 50% at a titer of approximately
1:150 in the ELISA. Note that anti-HVR1 rabbit hyperim-
mune serum did not inhibit binding of EC2 to soluble E2
(Table 1).
Deletion of the HVR1 region does not affect E2
conformation or binding to CD81 EC2
An infectious HCV cDNA clone mutated to delete the
HVR1 was still infectious when transfected into a chim-
panzee (Forns et al., 1999a), suggesting that the mutated
E2 remained functional. We first compared the reactivity
of the panel of monoclonal antibodies and rabbit hyper-
FIG. 2. Full-length E1 is not transported to the cytoplasmic mem
o the cell surface and full-length E1 were expressed simultan
ere detected in permeabilized cells (cytoplasmic staining). Howe
ells were transfected with pE1E2surf-715, which encodes the
ell surface.immune sera shown in Table 2 with cells transfected
with E1E2surf-715 or E1E2surf-715(DHVR1) plasmids.Both constructs encode a surface-expressed E2 trun-
cated at aa 715, but the latter has also had HVR1 deleted.
By immunofluorescence microscopy, the presence or
absence of HVR1 did not affect the staining of surface-
expressed E2, with the obvious exception of anti-HVR1
rabbit hyperimmune serum (Table 3). In additional exper-
iments, binding of conformation-sensitive MAbs (H2 and
H53) and EC2 of CD81 to modified forms of E2, with or
without HVR1, was tested by immunofluorescence mi-
croscopy (Table 3) and by flow cytometry. MAb H2 re-
acted equally well with surface-expressed E2 containing
(E2surf-661) or lacking [E2surf-661(DHVR1)] HVR1 (Fig.
4A). The results were similar for MAb H53 (data not
shown). Binding of the CD81 EC2 to E2surf-661 also was
not decreased by the removal of HVR1 (Fig. 4B). Deletion
of the HVR1 from E2surf-715 also did not diminish bind-
ing of either conformation-sensitive MAbs or CD81 EC2
(data not shown) (Table 3).
DISCUSSION
Thus far, attempts to develop a vaccine against HCV
have met with limited success. It seems evident that
alternative ways of presenting E1 or E2 to the immune
system will be required if antibodies that might neutralize
HCV are to be induced in sufficient quantities and with
appropriate specificities. Our previous demonstration
that a DNA vaccine encoding an E2 protein targeted to
the cell surface was more immunogenic than was one
encoding E2 that was retained in the ER (Forns et al.,
1999b) encouraged us to modify surface-expressed E2
by E2 modified for surface expression. E2 modified for transport
Both E1 (stained with rhodamine) and E2 (stained with FITC)
ly E2 was detected in nonpermeabilized cells (surface staining).
E1 protein and chimeric E2 modified for expression on thebrane
eously.
ver, on
entireand to characterize the mutated molecules for suitability
as possible vaccine components.
79CELL SURFACE-EXPRESSED HCV E2 GLYCOPROTEINSFIG. 3. E2surf-661 and E2surf-715 differ in their conformation and their ability to bind EC2 of CD81. (A) Nonpermeabilized cells, which had been
transfected with pE2surf-715 or pE2surf-661, were reacted with conformation-sensitive monoclonal antibody H2 or H53 or with recombinant CD81 EC2.
(B) Cells transfected with pDisplay, pE2surf-715, or pE2surf-661 were aliquoted, reacted with anti-HVR1 (reacts equally well with E2surf-661 and
E2surf-715) or MAb H2 (recognizes conformational epitope), and examined by flow cytometry. The results are presented as dot plots of forward scatter
(FSC-H, x axis) against FITC fluorescence intensity in the FL1-H channel ( y axis). In nonpermeabilized cells stained with anti-HVR1, 3.3% of cells
transfected with E2surf-661 scored positive and 2.2% of cells transfected with E2-surf-715 scored positive. Mean fluorescence intensity (513 and 458,
respectively) was similar. In contrast, when the same cell populations were stained with MAb H2, five times as many cells scored positive in the
E2surf-661 transfected cells than in the E2surf-715 transfected cells (1.37 and 0.24% respectively), and the mean fluorescence intensity (264 and 138,
respectively) differed by twofold. (C) Cells transfected with pDisplay, pE2surf-715, or pE2surf-661 were incubated with recombinant EC2 of CD81 and
then stained for both E2 (rabbit anti-HVR1/PE-labeled anti-rabbit) and EC2 (mouse monoclonal anti-thioredoxin/FITC-labeled anti-mouse). The results
are presented as dot plots of FITC fluorescence intensity in the FL1-H channel ( x axis) against PE fluorescence intensity in the FL2-H channel ( y axis).
Upper right quadrant: positive for both E2 and EC2; upper left quadrant: positive for E2 alone; lower right quadrant: positive for EC2 alone. The
percentage of transfected cells expressing E2 was 5.4% for E2surf-661 and 4.1% for E2surf-715 (background subtracted). The proportion of cells
expressing E2 (PE positive) that bound EC2 (FITC positive) was significantly higher for E2surf-661 (44%) than for E2surf-715 (3%).
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80 FORNS ET AL.In the current study, we demonstrated that either E1 or
E2 could be targeted to the cell surface by deletion of its
TMD and replacement with that of PDGFR, a cellular
protein normally expressed on the cell surface. However,
we found that full-length E1 containing its native TMD
TABLE 2
Reactivity of a Panel of Rabbit Hyperimmune Sera and Monoclonal
Antibodies to Different Forms of E2a
Antibody pE2b pE2surf-715c pE2surf-661c
LMF86 111 111 111
521 11 11 11
523 6 6 6
527 2 2 2
554 11 11 11
FOR-1 111 11 111
4E5 11 11 111
2H1 6 2 2
2G1 11 11 111
1H3 111 111 111
4F7 111 111 111
2H8 11 111 111
4F1 111 111 111
7B7 111 111 111
108d 11 111 111
503d 1 111 111
29E4 11 111 11
H2d 6 6 11
H53d 11 11 11
a LMF86, 521, 523, 527, 554, and FOR-1 are rabbit hyperimmune sera;
he rest are mouse (H2, H53) or human monoclonal antibodies. Reac-
ivity of antibodies to different forms of E2 was tested by immunofluo-
escence microscopy. Grading system from negative (2) to strongly
ositive (111). 6, weakly positive once, negative once.
b Permeabilized Huh-7 cells.
c Nonpermeabilized Huh-7 cells.
d Conformation-sensitive MAb.
T
Characterization of
Construct
Reactivity with conformation-sensit
H2 H53 108
pE2b 6 11 11
pE2surf-661d 11c 11c 111
pE2surf-715d 6c 11c 111
pE1E2surf-715d 6 11 111
pE2surf-661(DHVR1)d 11c 11c nd
pE2surf-715(DHVR1)d 6c 11c nd
pE1E2surf-715(DHVR1)d 6 11 11
a Antibody or EC2 binding to E2 was assayed by immunofluorescenc
6, weakly positive once, negative when retested. MAb, Monoclonal an
CD81. LMF86, RHS raised against the HVR1 (aa 390–410). FOR-1, RHS r
site of CD81; FOR-1 inhibits the binding of recombinant E2 to EC2. nd
b Reactivity to E2 was tested on permeabilized Huh-7 cells.
c Also tested by FACS analysis. All samples tested were confirmed positive
d Reactivity to surface-expressed E2 was tested on nonpermeabilized Huh-was not conveyed to the cell surface when coexpressed
with E2 modified for expression on the cell surface. Flint
et al. (1999b) recently reported that E1 was not trans-
ported to the cell surface when coexpressed with a
similarly modified E2 fused to a different TMD (from
influenza A virus HA protein). As proposed by Cocquerel
et al. (1999), these results suggest that E1 has its own ER
retention signal. Alternatively it is possible that deletion
of the E2 TMD abolished the interaction of E1 and E2, as
it is believed that these domains are involved in the
stabilization of E1/E2 heterodimers (Cocquerel et al.,
1998; Deleersnyder et al., 1997; Dubuisson et al., 1994).
or example, coexpression of E1 and modified forms of
2 lacking the E2 TMD did not lead to formation of E1/E2
eterodimers (Cocquerel et al., 1998). The failure of E1
nd E2 to interact in these circumstances may have
mplications for the construction of chimeras of HCV and
ther viruses, as the deletion or modification of the trans-
embrane domains could theoretically impede the for-
ation of functional heterodimers.
Data from our current study indicated that the extent of
he E2 truncation could significantly affect protein fold-
ng. A time-course analysis of transiently expressed E2
howed that E2surf-661 reached the cell surface at a
aster rate than did E2surf-715, suggesting that the addi-
ional residues in E2surf-715 limit the transport to the cell
urface. These results are in agreement with those ob-
ained previously for secreted forms of E2 (Michalak et
l., 1997). Since transport to the cell surface is an indirect
ndicator of proper folding, these results suggested that
2surf-661 acquired its correct conformation more rap-
dly than did E2surf-715 and/or that a greater proportion
f E2surf-715 misfolded and underwent subsequent deg-
adation. These data have implications for DNA immuni-
ation designed to present E2 on the cell surface, as the
binant E2 Proteins
bsa Reactivity with RHSa
Binding to CD81 EC2a503 LMF86 FOR-1
1 111c 111 11c
11 111c 111 11c
11 111c 11 6c
11 111 11 6
nd 2 111 11c
nd 2 11 6c
11 2 11 6
oscopy. Grading system from negative (2) to strongly positive (111).
s. RHS, rabbit hyperimmune serum. EC2, second extracellular loop of
gainst a linear epitope of E2 (aa 517–535) close to the putative binding
ne.ABLE 3
Recom
ive MA
1
1
1
e micr
tibodie
aised a
, not doby FACS.
7 cells.
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81CELL SURFACE-EXPRESSED HCV E2 GLYCOPROTEINSstrength of the immune response is highly dependent on
the amount of protein presented to the immune system.
Also important was the discovery that MAb H2 reacted
more efficiently with E2surf-661 than with E2surf-715.
This antibody recognizes E2 in well-folded E1/E2 het-
erodimers that are believed to represent functional units
of the envelope glycoproteins (Deleersnyder et al., 1997).
e do not have a precise explanation for the superior
eactivity of MAb H2 with E2surf-661. In general, it is
elieved that only proteins that have acquired a proper
onformation are transported from the ER to their final
estinations: misfolded or incompletely folded proteins
ndergo a “quality control” and are often retained in the
R and eventually degraded (Doms et al., 1993; Ham-
mond and Helenius, 1994). However, it was reported that
secreted forms of E2-661 consisted not only of mono-
meric glycoprotein that reacted with conformation-sensi-
tive MAbs but also of disulfide-bridged E2 aggregates
that did not react with these antibodies (Flint et al., 2000;
Michalak et al., 1997). These aggregates are believed to
result from a nonproductive folding pathway (Deleersny-
der et al., 1997; Dubuisson et al., 1994; Dubuisson and
Rice, 1996). The conformation-dependent MAbs H2 and
H53 specifically recognize non-disulfide-linked E2 and
are used to identify what are believed to be native forms
FIG. 4. Deletion of HVR1 does not significantly affect E2 conformatio
or pE2surf-661(DHVR1) were incubated with MAb H2 and examined b
(FSC-H, x axis) against FITC fluorescence intensity in the FL1-H channe
6.5% for pE2surf-661(DHVR1). (B) An aliquot of the same cells was in
proportion of positive cells was 3.5% for pE2surf-661 and 2.1% for pE2
intensity was ,1.5-fold.of the HCV glycoprotein complex (Deleersnyder et al.,
1997; Dubuisson et al., 1994; Grakoui et al., 1993; Micha-lak et al., 1997; Ralston et al., 1993). We found that Mabs
H2 and H53 both reacted strongly with E2surf-661 dis-
played on the surface of transfected cells but only MAb
H53 reacted comparably with similarly displayed E2surf-
715. Cocquerel et al. (1998) suggested that MAb H53
reacted differently with E2surf-717 and E2surf-661 in
pulse–chase experiments; however, as in our study, the
shorter and the longer forms of surface-expressed E2
were stained similarly when analyzed by flow cytometry.
The fact that E2surf-661 and E2surf-715 on the cell sur-
face were stained to equal extents with other antibodies
indicates that variation in the amount of protein accumu-
lated on the cell surface did not account for the different
patterns we observed with MAb H2. It appears most
likely that H2 has a lower affinity for E2surf-715 because
of changes in the particular conformational epitope rec-
ognized by this antibody. The fact that we did not find any
significant binding differences with other conformation-
sensitive MAbs (H53, 108 and 503) (Deleersnyder et al.,
1997; Habersetzer et al., 1998) suggests that the two
proteins are folded into native but not identical struc-
tures. Like MAb H2, CD81 EC2 bound to E2surf-661 much
more efficiently than it did to E2surf-715. These data are
important because they indicate that the definition of
native depends on the reagent used to measure it. The
nding to EC2 of CD81. (A) Cells transfected with pDisplay, pE2surf-661,
cytometry. The results are presented as dot plots of forward scatter
is). The proportion of cells stained with H2 was 7% for pE2surf-661 and
d with EC2 and stained with a mouse MAb against thioredoxin. The
(DHVR1) (background subtracted) and the difference in fluorescencen or bi
y flow
l ( y ax
cubatesignificance of this finding to vaccine development re-
mains to be determined.
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82 FORNS ET AL.We tested rabbit hyperimmune sera that recognized
different regions of E2 for their ability to inhibit the bind-
ing of E2 to CD81 EC2. The only antibody that inhibited
the binding of recombinant CD81 EC2 to a soluble E2
was directed against an epitope located at aa 517–535,
very close to the regions that Flint et al. (1999a) sug-
gested were involved in the interaction of E2 with CD81.
Interestingly, a human serum sample (H79) that neutral-
izes homologous HCV reacted strongly with a peptide
encoding this epitope and this sample also inhibited
binding of CD81 EC2 to soluble E2. The anti-HVR1 rabbit
hyperimmune serum, directed against the carboxy-termi-
nal 21 amino acids of HVR1, did not inhibit the binding of
EC2 to E2. Flint et al. (1999a) showed that a MAb against an
epitope at the amino-terminal end of HVR1 lost its ability to
recognize E2 after CD81 binding. Such a phenomenon
could not be observed using a polyclonal serum to HVR1,
as the reactivity to surface E2 of our anti-HVR1 rabbit
hyperimmune serum did not change after EC2 binding.
We were also interested in exploring whether deletion of
HVR1 would drastically alter the structure of the E2 protein.
Since HVR1 has been suggested to act as a decoy antigen
(Ray et al., 1999), immunization with E2 lacking the HVR1
might provide a useful approach for generating a qualita-
tively different immune response. Our in vitro data sug-
gested that deletion of HVR1 did not significantly change
the conformation of E2. First, deletion of HVR1 did not
abrogate transport of E2 to the cell surface. Second, the
reactivity of conformation-sensitive MAb H2 or H53 to E2
was not altered by deletion of HVR1. Furthermore, CD81
EC2 bound equally well to surface-expressed E2 lacking or
containing HVR1. We have recently reported that an HCV
cDNA clone lacking the HVR1 is infectious but attenuated in
vivo (Forns et al., 1999a). This result is in agreement with
ur in vitro data, as the conformational changes (if any)
nduced in E2 by deletion of HVR1 must be minimal since
nfectious virus was still assembled.
The current study demonstrated that various deletion
utants of the E2 protein of HCV could be transported to
nd expressed on the cell surface. Despite the fact that
2 truncated at either aa 661 or 715 could be targeted to
he cell membrane, the two molecules were morpholog-
cally and functionally different. In contrast, deletion of
he entire HVR1 did not seem to affect the folding of E2
r its ability to interact with the second extracellular loop
f CD81, the putative HCV receptor. These data are rel-
vant to the design of modified E2 proteins as vaccine
andidates. Furthermore, these data might prove helpful
n the construction of pseudotypes and chimeras be-
ween HCV and other viruses.
MATERIALS AND METHODS
onstruction of plasmidsWe prepared different expression vectors with HCV
nserts downstream from the CMV inmediate-early en-hancer-promoter and the T7 RNA polymerase binding
site. Construct pE2, encoding an intracellular form of
E2, contained the E1, E2, and p7 genes (aa 364–809),
cloned into pcDNA 3.1 (InVitrogen) (Forns et al.,
1999b). Plasmids pE2surf-715 and pE2surf-661 en-
coded truncated forms of E2 (aa 384–715 and aa 384–
661, respectively): each of the truncated E2 genes was
cloned into pDisplay (InVitrogen), in frame between a
signal sequence and a transmembrane domain se-
lected for cell-surface expression (Forns et al., 1999b).
Similarly, the pDisplay-based construct pE1surf-347
encoded a truncated form of E1 (aa 192–347) that was
expressed on the cell surface. Plasmid E1E2surf-715
consisted of the entire E1 gene followed by a trun-
cated E2 gene (encoding aa 192–715) cloned into
pDisplay, for expression of E2 on the cell surface. The
HCV inserts were in all cases amplified by PCR from
an infectious cDNA clone of strain H77, genotype 1a
(pCV-H77C) (Yanagi et al., 1997). The primers used are
listed in Table 4.
The pDisplay plasmid E1E2surf-715(HVR1) encoded
the entire E1 protein and a cell surface-expressed form
of the E2 protein (aa 192–715) lacking the HVR1 (aa
384–410). The plasmid was constructed by fusion PCR in
two steps: first, E1 and a truncated E2 lacking the HVR1
were amplified independently (primers E1-192BglII and
E1-383R 1 10 for E1 and E2-411 1 10 and E2-715PstI for
2). After purification, both PCR products were fused by
CR using the external primers (E1-192BglII and E2-
15-PstI). cDNAs encoding truncated forms of E2 lacking
he HVR1 [pE2surf-661(DHVR1) and pE2surf-715(DHVR1)]
were derived from pE1E2surf-715(DHVR1) by PCR and
then cloned into pDisplay.
For cloning, PCR products were digested with the
indicated restriction enzymes and ligated into the indi-
cated vectors using standard methods (Forns et al.,
1999b). All clones were sequenced to ensure that the
DNA encoded the authentic HCV sequence.
Immunofluorescence and flow cytometry
To determine the cell compartment in which the differ-
ent forms of E2 were expressed, Huh-7 cells were tran-
siently transfected with different constructs and analyzed
by immunofluorescence and/or flow cytometry. The re-
activity of the different forms of the E2 protein with a
panel of well-characterized rabbit hyperimmune sera
and human or mouse monoclonal antibodies was ana-
lyzed. Human monoclonal antibodies 4E5, 2H1, 2G1, 1H3,
4F7, 2H8, 4F1, and 7B7 were provided by Dr. M. Cardoso
(da Silva Cardoso et al., 1998), human monoclonal
antibodies 108, 503, and 29E4 were provided by Dr. G.
Inchauspe (Habersetzer et al., 1998), and mouse mono-
clonal antibodies H2 and H53 were provided by Dr. J.
Dubuisson (Deleersnyder et al., 1997). MAbs H2, H53,
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83CELL SURFACE-EXPRESSED HCV E2 GLYCOPROTEINS108, and 503 recognize E2 in well-folded E1/E2 het-
erodimers.
Huh-7 cells were cultured in Dulbecco’s modified Ea-
gle’s medium (Life Technologies) containing 10% bo-
vine serum (BioWhitaker) and penicillin–streptomycin
(Sigma). Cells grown in 4-well tissue culture chambers
were screened for the expression of E2 glycoprotein
after DNA transfection, as previously described (Forns et
al., 1999b). Cells were fixed and permeabilized with cold
acetone for 3 min (intracellular expression) or nonper-
meabilized cells were stained directly (surface expres-
sion).
For simultaneous detection of E1 and E2 proteins,
cells were double-stained with mouse monoclonal anti-
body A4 against E1 (kindly provided by Dr. H. Greenberg)
(Deleersnyder et al., 1997; Dubuisson et al., 1994) in
combination with a human or chimpanzee serum that
contained anti-E2 but not anti-E1. Secondary antibodies
were FITC goat anti-mouse and rhodamine goat anti-
human (Pierce).
The interaction of different forms of E2 with antibodies
(or CD81) was quantified by a flow cytometry-based
assay using a FACScan apparatus (Becton Dickinson).
Huh-7 cells in 6-cm plates were transfected, scraped
from the wells, resuspended in PBS with 5% bovine
serum albumin (BSA), and stained. For intracellular stain-
ing, cells were fixed and permeablized by a cold ace-
tone/methanol mixture (1/1) for 3 min. After two washes
with PBS/5% BSA, cells were resuspended in 200 ml of
PBS/5% BSA and incubated with the primary antibody for
40 min at room temperature. After one wash with PBS/5%
BSA, cells were resuspended in 200 ml of PBS/5% BSA
ontaining the secondary antibody, for 30 min at room
emperature. After two washes with PBS/5% BSA, cells
ere analyzed by FACS. For cell-surface analysis, cells
T
Primers Used for C
E2-364NheI 59-CG
E2-809HindIII 59-AC
E2-384BglII 59-AC
E2-715PstI 59-AC
E2-661PstI 59-AC
E1-383R (110) 59-TCA
E2-411S (110) 59-CG
E1-192BglII 59-AC
E1-347PstI 59-AC
CD81 19S 59-AC
CD81-693AS 59-CC
Note. Primers used for construction of pE2 (E2-364NheI and E2-80
pE2surf-661 and pE2surf-661(DHVR1) (E2-384BglII and E2-661PstI), pE
and E1-383R 1 10, E2-411 1 10 and E2-715PstI, E1-192BglII, and E2
CD81-693AS were used for amplification of CD81 EC2.ere neither fixed nor permeabilized but the rest of the
taining procedure was the same.
A
Sabbit hyperimmune sera
Antibodies against different domains of the E2 protein
ere generated by immunizing rabbits with peptides
ontained within the E2 protein of strain H77 (Table 1).
our peptides were selected, based on a predicted high-
ntigenicity index (GeneWorks, Oxford Molecular Group).
n additional peptide encompassing the 21 C-terminal
mino acids of the HVR1 of E2 (Farci et al., 1996) was
lso used in the study. Peptides were synthesized (Pio-
eer Peptide Synthesis System Multiple Peptide Synthe-
is accessory; Perseptive Biosystems), HPLC purified,
nd conjugated to keyhole limpet hemocyanin. Individual
abbits were immunized with one peptide, boosted at
eeks 2 and 4, and exsanguinated at week 10. The
eactivity of rabbit sera was analyzed by ELISA based on
soluble recombinant E2 protein (Lesniewski et al.,
995) (aa 388–664, kindly provided by Dr. I. K. Mushah-
ar, Abbott Laboratories), by immunofluorescence mi-
roscopy (Forns et al., 1999b), by Western blot (Forns et
l., 1999b), and by immunoprecipitation (Table 1).
Immunoprecipitation studies utilized metabollically la-
eled E2. Huh-7 cells cultured in 6-cm plates were trans-
ected with pE2surf-715; 24 h after transfection, cells
ere washed with methionine-free medium (Life Tech-
ologies) and incubated with 1 ml of methionine-free
edium containing 50 mCi [S35]Met (Amersham) for 4 h.
hereafter, cells were lysed with Tris- buffered saline
TBS), 1% NP-40, and 1 mM EDTA for 10 min on ice. Cell
ysates were incubated with an equal volume of protein
–Sepharose (Pharmacia) on ice for 1 h to reduce non-
pecific binding and then 25–50 ml of treated lysate was
ncubated with 1–2 ml of rabbit hyperimmune serum in 20
ml of immunoprecipitation buffer (TBS, 1% NP-40, and 1
mM EDTA) overnight at 4°C. Thereafter, 100 ml of protein
–Sepharose was added and incubated for 1 h at 4°C.
ction of Plasmids
AGCATGGTGGGGAACTGGGCGAAGGTCCTGG 39
AGCTTTTACTATGCGTATGCCCGCTGAGGCAACGCC 39
GATCTGAAACCCACGTCACCGGGGGAAATGCC 39
TGCAGCTTAATGGCCCAGGACGCGATGCTTG 39
TGCAGCTCGGACCTGTCCCTGTCTTCCAG-39
GATCGCGTCGACGCCGGCAAATAGCAG-39
GCGATCCAACTGATCAACACCAACGGC-39
GATCTTACCAAGTGCGCAATTCCTCGGGG-39
TGCAGCATGTCCATGATGGCTTGTGGGATCCG-39
GCATCAAGTACCTG-39
CCACAGCACAGCAC-39
I), pE2surf-715 and pE2surf-715(DHVR1) (E2-384BglII and E2-715PstI),
f-715 (E1-192BglII and E2-715PstI), pE1E2surf-715(DHVR1) (E1-192BglII
tI), pE1surf-347 (E1-192BglII and E1-347PstI). Primers CD81 19S andABLE 4
onstru
TCGCT
GCGTA
GCGTA
GCGTC
GCGTC
GTTG
TCGAC
GCGTA
GCGTC
CAAGT
GGATG
9HindII
1E2surfter three washes, bound proteins were eluted with
DS–loading buffer and electrophoresed on polyacryl-
t
a
w
(
D
84 FORNS ET AL.amide gels. The gels were dried and exposed to film in
the presence of an intensifying screen.
Cloning, expression, and purification of CD81
EC2 of human CD81 was expressed in fusion with
thioredoxin, as previously described (Pileri et al., 1998).
RNA was extracted from Huh-7 cells with Trizol (Life
Technologies). Sequence encoding EC2 was amplified
by RT-nested PCR with the primers CD81-19S and CD81-
693AS (Table 4) for first PCR and primers For-hEC2 and
Rev-hEC2 (Pileri et al., 1998) for the second PCR. The
PCR product was digested with XhoI and HindIII and
ligated to the vector pThioHisC (InVitrogen). The insert
was sequenced, and the fusion protein was expressed in
Escherichia coli TOP-10 (InVitrogen) and purified using a
nickel-chelating Sepharose resin (ProBond, InVitrogen).
The identity of the fusion protein was confirmed by SDS–
PAGE analysis and Western blot with antibodies to thi-
oredoxin (Anti-Thio monoclonal antibody, InVitrogen) or
CD81 (anti-CD81 polyclonal goat serum, Santa Cruz Bio-
technology).
FACS and immunofluorescence analysis. Huh-7 cells
transfected with pE2surf-661, pE2surf-715, pE2surf-
661(DHVR1), pE2surf-715(DHVR1), or pDisplay were an-
alyzed for interaction with CD81 EC2 48 h after transfec-
tion. For FACS analysis, transfected cells were scraped
from 6-cm plates, pelleted, and incubated with thiore-
doxin-EC2 (at a final concentration of approximately 5
mg/ml) for 1 h at 4°C. Cells were washed with PBS/5%
BSA and incubated with a mouse MAb directed against
thioredoxin, washed, and incubated with a goat anti-
mouse FITC-labeled antibody. Cells were washed twice
with PBS/5% BSA and analyzed by flow cytometry. E2 and
CD81 EC2 were simultaneously detected with a rabbit
hyperimmune serum against HVR1 (LMF86) and the anti-
thioredoxin MAb. Dual staining was performed with a
donkey anti-rabbit R-phycoerythrin-labeled antibody (Ac-
curate) and a donkey anti-mouse FITC-labeled antibody
(Accurate), both preadsorbed against relevant species to
avoid cross-reactivity. For immunofluorescence, we incu-
bated transfected cells with thioredoxin–EC2 (at a final
concentration of approximately 5 mg/ml) for 1 h at 37°C
(in a CO2 incubator) and detected binding with the anti-
hioredoxin MAb followed by staining with the donkey
nti-mouse FITC-labeled antibody.
Blocking experiments. A microtiter plate (Costar 3690)
as coated with recombinant soluble E2 protein
Lesniewski et al., 1995) at 2 mg/ml at 4°C overnight,
blocked with 5% nonfat dry milk in PBS for 1 h at room
temperature, and then incubated with various dilutions of
rabbit sera for 2 h at room temperature. After four
washes with PBS with 0.05% Tween 20, thioredoxin–EC2
was added at 0.5 mg/ml diluted in PBS with 0.05% Tween
20 and 1% BSA, followed by another 2-h incubation at
room temperature. The plate was washed and an anti-thioredoxin MAb (InVitrogen) was added for 1 h followed
by washing and incubation with alkaline phosphatase-
conjugated antibody to mouse IgG (preadsorbed; Pierce)
for 1 h. Substrate (p-nitrophenyl phosphate, Sigma) was
added and readings were taken at an OD of 405 nm after
30 min. OD values obtained with various serum dilutions
were compared with the OD of wells lacking serum, and
the serum dilution required for 50% inhibition of OD was
calculated. Human serum H79, previously demonstrated
to inhibit E2–CD81 interaction (Pileri et al., 1998) (per-
formed by Dr. Chien, Chiron), was used as a positive
control.
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